Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

10.71 -0.73 (-6.38%)
Streaming Delayed Price Updated: 12:48 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
News headline image
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome ↗
SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon. 
Via Benzinga
News headline image
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
From SciSparc Ltd
Via GlobeNewswire
News headline image
Why Is SciSparc (SPRC) Stock Up 94% Today? ↗
SciSparc stock is up on Thursday with heavy trading of SPRC shares after it provided an update on its merger with AutoMax. 
Via InvestorPlace
News headline image
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy ↗
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy. 
Via Benzinga
Topics Intellectual Property
News headline image
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
From SciSparc Ltd
Via GlobeNewswire
News headline image
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
From SciSparc Ltd
Via GlobeNewswire
News headline image
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
From SciSparc Ltd
Via GlobeNewswire
News headline image
Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients ↗
SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at... 
Via Benzinga
News headline image
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy ↗
SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milestones of $3M in cash plus royalties. 
Via Benzinga
News headline image
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
From SciSparc Ltd
Via GlobeNewswire
News headline image
Nasdaq Jumps Over 2%; Walmart Earnings Top Views ↗
 
Via Benzinga
News headline image
Dow Surges Over 500 Points; US Retail Sales Rise In July ↗
 
Via Benzinga
Topics Stocks
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today! 
Via InvestorPlace
News headline image
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
SciSparc Updates Regarding the Status of the AutoMax Merger
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.